Hytest is excited to announce the launch of a new antibody: Recombinant Anti-Human Carcinoembryonic Antigen (CEA) (Cat. # 4CA30cc, MAb: RE16).

CEA is a protein produced in gastrointestinal tissue during foetal development, with production typically ceasing before birth. As a result, CEA is usually found at very low levels in the blood of healthy adults. It serves as a tumor marker, most commonly measured in blood to help detect and monitor certain types of cancer.

Elevated CEA levels may indicate cancers of the colon and rectum, as well as the prostate, ovaries, lungs, thyroid, or liver. The CEA blood test is used to monitor treatment effectiveness, assess cancer staging, and detect recurrence after treatment. In some cases, elevated CEA can also be associated with non-cancerous conditions such as cirrhosis, benign breast disease, or emphysema.

RE16, produced using advanced recombinant technology, is suitable for CEA assay development and delivers reliable performance with consistent quality across production lots. Its high-yield expression system supports a stable, long-term supply, making it a dependable choice for scaling applications and reducing supply risk for customers.

For more detailed information, please refer to datasheet on the product page, or contact our Sales.